Hereditary Hemorrhagic Telangiectasia (HHT) Center | HRSA 26 092

Frequently Asked Questions (FAQs) - HRSA Hereditary Hemorrhagic Telangiectasia (HHT) Center Program

What is the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program?

The HHT Center Program is a federal funding opportunity from the Health Resources and Services Administration (HRSA) intended to reduce illness and prevent deaths associated with hereditary hemorrhagic telangiectasia (HHT). The program supports a coordinated, systems-based approach to improving how HHT is identified, diagnosed, and managed in real-world clinical settings.

What is hereditary hemorrhagic telangiectasia (HHT), and why is it a focus of this program?

HHT is described in the opportunity as a rare disorder that can cause abnormal blood vessel formation and serious complications, especially when it is missed or treated late. Because HHT is rare and often underdiagnosed, the program emphasizes earlier identification, more reliable diagnosis, and better-organized care pathways to improve outcomes.

What is the main goal of this funding opportunity?

The overall goal is to strengthen real-world clinical capacity by partnering with a clinical center to improve how HHT care is delivered, coordinated, and expanded to more patients. A core theme is moving beyond isolated care toward a more connected, systems-based model that supports earlier case-finding, more dependable diagnosis, and improved outcomes.

What kinds of activities does the program emphasize to improve HHT detection and diagnosis?

The program expects the funded effort to create innovative strategies that help clinicians identify and diagnose HHT. Based on the description, this includes building or enhancing clinical workflows, referral networks, and provider support tools so that frontline clinicians and specialists can recognize HHT, assess patients appropriately, and connect them to coordinated care.

Does the program focus on expanding access to HHT expertise beyond one clinic?

Yes. The opportunity emphasizes expanding access, meaning the project is intended to extend specialized knowledge and coordinated services beyond a single clinic into broader care settings where patients may first present and where specialized evaluation and management may not currently be available.

How does the opportunity describe improving coordination of HHT care?

It describes improving care delivery and coordination through more organized treatment pathways and structured coordination models. The intent is to reduce delays and gaps in care by connecting clinicians and systems so potential cases can be recognized earlier and patients can reach appropriate evaluation and management more reliably.

What is the patient registry deliverable, and what is it intended to do?

A major deliverable is the development of a de-identified, aggregate patient data registry. The registry is intended to strengthen the evidence base for understanding HHT as a rare disease and for evaluating treatment outcomes over time by tracking patterns in diagnosis, care coordination, interventions, and outcomes.

What does it mean that the registry data will be "de-identified" and "aggregate"?

As described, the registry will focus on de-identified and aggregate data to protect individual patient privacy while still enabling meaningful analysis across a larger patient population than a single practice might usually see.

How is the registry expected to help improve HHT care?

The registry is positioned as a learning tool that can help evaluate how HHT is treated and what outcomes patients experience over time. By analyzing aggregate trends, the project can identify what works best, where gaps remain, and how effective care models can be improved and replicated.

What type of federal award is this?

This opportunity is offered as a discretionary cooperative agreement. The description notes that this generally indicates HRSA expects substantial involvement in the project’s direction, coordination, or oversight compared with a standard grant.

Which federal agency is offering the HHT Center Program opportunity?

The funding opportunity is offered by the Health Resources and Services Administration (HRSA).

What is the activity category for this opportunity?

The activity category listed is health.

What is the CFDA number associated with this program?

The Catalog of Federal Domestic Assistance (CFDA) number listed is 93.110.

What is the funding opportunity number?

The funding opportunity number is HRSA 26 092.

How many awards does HRSA expect to make under this opportunity?

The opportunity indicates that HRSA plans to make a single award (expected awards: 1).

What is the maximum award amount (ceiling) for this opportunity?

The maximum award amount (ceiling) is $2,900,000.

When was this opportunity created?

The opportunity was created on 2026-06-08.

What is the application closing date?

The original application closing date is 2026-07-10.

Who is eligible to apply according to the information provided?

Eligibility is listed as state governments.

Which jurisdictions are included under the opportunity's definition of "domestic"?

The opportunity notes that "domestic" includes the 50 states and the District of Columbia, Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, and the Freely Associated States: the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.

What kind of overall approach is this program trying to build for HHT care?

The program is structured to support a centrally coordinated initiative that pairs specialized clinical leadership with broader systems-building. The described approach focuses on improving detection and diagnosis, expanding coordinated access to care, and generating a privacy-protective registry to clarify treatment patterns and outcomes.